Geron (NASDAQ:GERN) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Geron Corporation (NASDAQ:GERN) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.31 and traded as high as $1.6275. Geron shares last traded at $1.61, with a volume of 15,384,327 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. TD Cowen restated a “buy” rating on shares of Geron in a research report on Thursday, January 29th. UBS Group restated a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. Needham & Company LLC lowered their price target on Geron from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. HC Wainwright reiterated a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $2.75.

Geron Price Performance

The firm has a market capitalization of $1.03 billion, a P/E ratio of -13.42 and a beta of 0.62. The stock’s 50 day simple moving average is $1.36 and its 200 day simple moving average is $1.31. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.87 and a current ratio of 5.96.

Institutional Trading of Geron

Institutional investors and hedge funds have recently made changes to their positions in the company. 55 North Private Wealth LLC bought a new position in Geron during the 4th quarter worth about $29,000. LCM Capital Management Inc boosted its stake in shares of Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,000 shares in the last quarter. Swiss Life Asset Management Ltd increased its holdings in Geron by 73.6% during the third quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 11,182 shares during the period. Savant Capital LLC increased its holdings in Geron by 73.8% during the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 11,074 shares during the period. Finally, Fisher Asset Management LLC bought a new position in Geron in the third quarter worth approximately $37,000. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.